TCM
DNLI icon

Tao Capital Management’s Denali Therapeutics DNLI Stock Holding History

Tao Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,042
Closed -$66K – 11
2023
Q4 		$66K Buy
+3,042
New +$60.2K 0.06% 11
2023
Q3 		– Sell
-3,651
Closed -$108K – 12
2023
Q2 		$108K Buy
+3,651
New +$103K 0.08% 13
2021
Q4 		– Sell
-38,949
Closed -$1.97M – 16
2021
Q3 		$1.97M Buy
+38,949
New +$2.2M 0.52% 13
2021
Q2 		– Sell
-6,086
Closed -$348K – 10
2021
Q1 		$348K Buy
+6,086
New +$407K 0.1% 8

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tao Capital Management's DNLI Position: Q1 2024 in Review

Tao Capital Management sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 3,042 shares — an estimated $66K sold.

Tao Capital Management first reported a position in DNLI in Q1 2021 and held it in 4 quarters. The position peaked at $1.97M in Q3 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Tao Capital Management reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Tao Capital Management sold 3,042 Denali Therapeutics shares in Q1 2024, an estimated $66K.
  • Tao Capital Management first reported a position in Denali Therapeutics in Q1 2021 and held it in 4 quarters.
  • Tao Capital Management's Denali Therapeutics position peaked at $1.97M in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Tao Capital Management's 13F filing for Q1 2024, filed 9 May 2024.